Consultation on the Prescription Drug List: Naloxone
The purpose of this Notice of Consultation is to provide an opportunity to comment on the proposal to revise the qualifier for Naloxone on the Prescription Drug List (PDL).
How to Get Involved
This consultation is open for comment until January 26, 2017. Please read through the information provided in the link below titled “Consultation Document”. Once read, please submit your comments via email, facsimile or by mail to:
Prescription Drug Status Committee
Address Locator 3102C3
Holland Cross, Tower B
1600 Scott Street
Interested parties are encouraged to provide comments and suggestions by January 26, 2017.
Reporting to Canadians
The results of the consultation will be made available on this website.
If you have any questions, contact us the Prescription Drug Status Committee.
Report a problem or mistake on this page
- Date modified: